An interventional study of CPAP in Sleep Apnea, Obstructive, sponsored by Alberto Alonso Fernandez. Completed at 2 sites in Spain. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Alberto Alonso Fernandez · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Sleep Apnea, Obstructive with a site in Spain — 16 open to participants now, 19 under way, 6 of them phase 3. Sleep Apnea, Obstructive · Spain.
Among the 82 studies in Sleep Apnea, Obstructive with a site in Spain, this one is the 29th largest by enrollment of the 60 interventional ones that give a count, is one of 5 that started in 2020, is one of 46 with no phase, and was the 52nd registered.
2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.
Browse Sleep Apnea, Obstructive studies →16 of the 82 studies in Sleep Apnea, Obstructive with a site in Spain are open now. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in Spain, United States, Australia and 7 more countries
Ages 18+
Novo Nordisk A/S · Sites in Spain, United States, Australia and 7 more countries
Ages 18+
Eli Lilly and Company · Sites in Spain, United States, Australia and 8 more countries
Ages 18+
Sociedad Española de Neumología y Cirugía Torácica · Sites in Spain
Ages 18+
Hospital Clinic of Barcelona · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 5 started in 2020.
This study's enrollment of 130 is above the median of 52 across 1,476 interventional studies indexed under Sleep Apnea, Obstructive.
Median enrollment 128 across the 60 interventional studies, 338 across the 21 observational. Of the 44 that completed or were terminated, 3 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 82 have an industry lead sponsor. The 10 most frequent:
Alberto Alonso Fernandez is the lead sponsor of 2 studies on the registry; none are open to participants now.
Alberto Alonso Fernandez has 2 studies filed under Sleep Apnea, Obstructive — fewer than ten, so there is no comparison to draw.
3 of the studies in Sleep Apnea, Obstructive with a site in Spain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07225686Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | 2027-08-20 |
| NCT07226765Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | 2027-08-30 |
| NCT07001215Hospital Universitario Ramon y CajalEffect of CPAP Versus APAP in Patients With Obesity Undergoing Bariatric Surgery Protocol | 2027-09-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 82 studies in Sleep Apnea, Obstructive with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Clinical trial on the effect of continuous positive pressure (CPAP). Objectives: 1) To assess the total or partial recovery of oxidative and inflammatory damage after recovering IH. 2) To check whether the results obtained in vitro on the recovery of the damage according to the form of manifestation of IH are validated in SAHS patients. 3) To determine if CPAP reduces nighttime blood pressure and arterial stiffness depending on whether or not patients have a non-dipping pattern of blood pressure and depending on the degree of correction of IH. 4) To clarify whether residual nocturnal hypoxemia influences the recovery of oxidative and inflammatory damage in patients. 5) To determine nasal and intestinal microbioma and the effect of CPAP treatment
Design: Randomized, parallel group, non-blinded, controlled clinical trial compared with conventional treatment.
A. Protocol and intervention Patients with an AHI>30 h-1 will be assigned, using a 1:1 randomization table, to lifestyle recommendations treatment or to lifestyle recommendations plus nasal CPAP, for a period of 4 months. CPAP pressure will be titled with automatic using an AutoSet II device, ResMed.
B. Sample size For the estimation of the sample size, previous data from our group were used. In this case, in order to compare the effect of CPAP in a subgroup of patients with well-controlled OSA and in another with residual hypoxemia; it would be necessary to randomize a total of 100 patients with OSA.
C. Ethical considerations
D. Methods
Statistic analysis The data will be expressed as mean ± standard deviation, median (interquartile range) or percentage, depending on their type and distribution. For comparison between groups Student's t-test, the U-Mann-Whitney or the chi-square test will be used, as appropriate. The relations between variables will be analyzed using Pearson's correlation and multiple linear regression analysis. The effect of treatment will be evaluated using analysis of covariance (ANCOVA) to compare the change in log-transformed 8-isoprostane for the CPAP versus the usual care group, with the treatment group as a factor, and baseline 8-isoprostane, body mass index, smoking, and age as covariates. Intention-to-treat analysis included all randomized patients, whereas the per-protocol analysis set was defined as all patients in the full analysis who completed the study and, in the group treated with CPAP, achieved adherence greater than 4 hours per night. A multiple logistic regression model will be applied to determine the related variables with a response to treatment. Values of p \<0.05 will be considered statistically significant. The statistical study will be performed with the SPSS program version 15.0.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diet and general life style recommendations plus continuous positive airway pressure (CPAP).
Device: CPAP
Diet and general life style recommendations.
Continuous positive airway pressure
Change from baseline in 8 isoprostane levels
To compare the change in 8 isoprostane levels between the patients allocated to CPAP group and the control group
Time frame: 4 months
Change from baseline in microbiota population diversity from stool samples
To compare the change in in microbiota population diversity, after massive sequencing and amplification of the 16S rRNA gene from stool samples between the patients allocated to CPAP group and the control group
Time frame: 4 months
Change from baseline in microbiota population diversity from nasopharyngeal samples
To compare the change in microbiota population diversity, after massive sequencing and amplification of the 16S rRNA gene from nasopharyngeal samples between the patients allocated to CPAP group and the control group
Time frame: 4 months
Change from baseline in microbiota population abundance from stool samples
To compare the change in microbiota population abundance, after massive sequencing and amplification of the 16S rRNA gene from stool samples between the patients allocated to CPAP group and the control group
Time frame: 4 months
Change from baseline in microbiota population abundance from nasopharyngeal samples
To compare the change in microbiota population abundance, after massive sequencing and amplification of the 16S rRNA gene from nasopharyngeal samples between the patients allocated to CPAP group and the control group
Time frame: 4 months
Change from baseline in microbiota population color maps from stool samples
To compare the change in microbiota population color maps, after massive sequencing and amplification of the 16S rRNA gene from stool samples between the patients allocated to CPAP group and the control group
Time frame: 4 months
Change from baseline in microbiota color maps from nasopharyngeal samples
To compare the change in microbiota population color maps, after massive sequencing and amplification of the 16S rRNA gene from nasopharyngeal samples between the patients allocated to CPAP group and the control group
Time frame: 4 months
Augmentation index (%)
To compare Augmentation index (%) in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group.
Time frame: Baseline and 4 months
Pulse wave velocity (m/sec)
To compare pulse wave velocity (m/sec) in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group.
Time frame: Baseline and 4 months
Aortic systolic blood pressure central (mmHg)
To compare systolic blood pressure central (mmHg) in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group.
Time frame: Baseline and 4 months
Diastolic blood pressure central (mmHg)
To compare diastolic blood pressure central (mmHg) in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group.
Time frame: Baseline and 4 months
Subendocardial viability ratio (%)
To compare subendocardial viability ratio (%) in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group.
Time frame: Baseline and 4 months
Central augmentation pressure (mmHg)
To compare central augmentation pressure (mmHg) in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group.
Time frame: Baseline and 4 months
Time to reflection (ms)
To compare time to reflection (ms) in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group.
Time frame: Baseline and 4 months
Peripheral systolic blood pressure (mmHg)
To compare peripheral systolic blood pressure (mmHg) in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group.
Time frame: Baseline and 4 months
Peripheral diastolic blood pressure (mmHg)
To compare diastolic blood pressure central (mmHg) in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group.
Time frame: Baseline and 4 months
Nocturnal blood pressure dipping
To compare number of patients with nocturnal blood pressure dipping in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group.
Time frame: Baseline and 4 months
Nocturnal hypertension.
To compare number of patients with nocturnal hypertension in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group.
Time frame: Baseline and 4 months
Patients with undiagnosed hypertension
To compare number of patients with undiagnosed hypertension in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group.
Time frame: Baseline and 4 months
C-reactive protein (CRP)
To compare CRP in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group.
Time frame: Baseline and 4 months
Homocysteine
To compare homocysteine (μmol/L) in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group.
Time frame: Baseline and 4 months
Endothelin
To compare endothelin levels in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group.
Time frame: Baseline and 4 months
Angiotensin
To compare angiotensin levels in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group
Time frame: Baseline and 4 months
8 isoprostane levels in OSA and in non-OSA patients
To compare 8 isoprostane levels in OSA and in non-OSA patients.
Time frame: Baseline
Lipid profile
To compare lipid profile with same units of measure (all in mg/dL) in OSA and in non-OSA patients and to compare baseline (OSA vs. non-OSA), and the change from baseline in lipid profile between the patients allocated to CPAP group and the control group.
Time frame: Baseline and 4 months
Circulating inflammatory proteomic profile in OSA
To compare the circulating inflammatory proteomic profile using proximity expression assay technology (Olink®, Sweden, which comprised 96 proteins. All data are expressed as normalized protein expression values) in OSA and in non-OSA patients and to compare the change from baseline the circulating inflammatory proteomic profile between the patients allocated to CPAP group and the control group.
Time frame: Baseline and 4 months
Systemic inflammation.
To compare systemic inflammation (IL1bbeta IL-6, IL-8, HIF1 alpha, TNF-1alpha) with same units of measure (all in pg/mL) in OSA and in non-OSA patients and to compare the change from baseline between the patients allocated to CPAP group and the control group.
Time frame: Baseline and 4 months
Intake-regulating hormones.
To compare intake-regulating hormones with same units of measure (all in µg/mL) in OSA and in non-OSA patients and to compare the change from baseline between the patients allocated to CPAP group and the control group.
Time frame: Baseline and 4 months
Change from baseline in number of patients with desaturation index >3%
To compare the change from baseline in number of patients with desaturation index ≥ 5 h-1, ≥ 15 h-1, and ≥ 30 h-1 between the patients allocated to CPAP group and the control group
Time frame: 4 months
Microbiota population abundance from stool and nasopharyngeal samples in OSA and in non-OSA patients
To compare microbiota population abundance from stool and nasopharyngeal samples in OSA and in non-OSA patients
Time frame: Baseline
Microbiota population diversity from stool and nasopharyngeal samples in OSA and in non-OSA patients
To compare microbiota population diversity from stool and nasopharyngeal samples in OSA and in non-OSA patients
Time frame: Baseline
Microbiota population color maps from stool and nasopharyngeal samples in OSA and in non-OSA patients
To compare microbiota population color maps from stool and nasopharyngeal samples in OSA and in non-OSA patients
Time frame: Baseline
Relationships of microbiota population diversity from stool and nasopharyngeal samples in OSA to blood pressure profile.
To relate microbiota population diversity from stool and nasopharyngeal samples to blood pressure profile.
Time frame: Baseline and 4 months
Relationships of microbiota population abundance from stool and nasopharyngeal samples in OSA to blood pressure profile
To relate microbiota population diversity from stool and nasopharyngeal samples to blood pressure profile.
Time frame: Baseline and 4 months
Relationships of microbiota population color maps from stool and nasopharyngeal samples in OSA to blood pressure profile
To relate microbiota population color maps from stool and nasopharyngeal samples to blood pressure profile.
Time frame: Baseline and 4 months
Relationships of microbiota population diversity from stool and nasopharyngeal samples in OSA to augmentation index.
To relate microbiota population diversity from stool and nasopharyngeal samples to augmentation index.
Time frame: Baseline and 4 months
Relationships of microbiota population abundance from stool and nasopharyngeal samples in OSA to augmentation index.
To relate microbiota population diversity from stool and nasopharyngeal samples to augmentation index.
Time frame: Baseline and 4 months
Relationships of microbiota population color maps from stool and nasopharyngeal samples in OSA to augmentation index.
To relate microbiota population color maps from stool and nasopharyngeal samples to augmentation index.
Time frame: Baseline and 4 months
Relationships of microbiota population diversity from stool and nasopharyngeal samples in OSA to pulse wave velocity.
To relate microbiota population diversity from stool and nasopharyngeal samples to pulse wave velocity.
Time frame: Baseline and 4 months
Relationships of microbiota population abundance from stool and nasopharyngeal samples in OSA to pulse wave velocity.
To relate microbiota population diversity from stool and nasopharyngeal samples to pulse wave velocity.
Time frame: Baseline and 4 months
Relationships of microbiota population color maps from stool and nasopharyngeal samples in OSA to pulse wave velocity.
To relate microbiota population color maps from stool and nasopharyngeal samples to pulse wave velocity.
Time frame: Baseline and 4 months
Vitamin D
To compare Vitamin D levels in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group
Time frame: Baseline and 4 months
Glucose metabolism indices
To compare glucose metabolism indices \[(hemoglobin A1c, fasting insulin level, homeostasis model assessment of insulin resistance (HOMA-IR), Quantitative Insulin Sensitivity Check Index (QUICKY) and triglyceride-glucose index, triglyceride glucose-waist circumference, triglyceride glucose-Body Mass index\] in OSA and in non-OSA patients and to compare the change from baseline between the patients allocated to CPAP group and the control group
Time frame: Baseline and 4 months
Hematological prognostic biomarkers
To compare neutrophil to lymphocyte, hemoglobin-to-red cell distribution width in OSA and in non-OSA patients and to compare the change from baseline between the patients allocated to CPAP group and the control group.
Time frame: Baseline and 4 months
Obesity indices
To compare body mass index, body fat composition in OSA and in non-OSA patients and to compare the change from baseline between the patients allocated to CPAP group and the control group
Time frame: Baseline and 4 months
Ambulatory blood pressure monitoring (mmHg)
To compare 24-hour (systolic blood pressure, diastolic blood pressure, mean blood pressure, daytime systolic blood pressure, daytime diastolic blood pressure, daytime mean blood pressure, nighttime systolic blood pressure, nighttime diastolic blood pressure, nighttime mean blood pressure) (all in mmHg) in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group
Time frame: Baseline and 4 months
Nocturnal oxygenation indices
To compare (oxygen desaturación index, time spent with oxygen saturation below 90%) in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group.
Time frame: Baseline and 4 months
Change from baseline in number of patients with Obesity
To compare the change from baseline in number of patients with obesity and abdominal obesity between the patients allocated to CPAP group and the control groups
Time frame: 4 months
Daytime hypersomnolence
To compare Epworth sleepiness scale (ESS) and number of patients with ESS \>10 in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group.
Time frame: Baseline and 4 months
Change from baseline in number of patients with metabolic syndrome or prediabetes
To compare the change from baseline in number of patients with metabolic syndrome and prediabetes profile between the patients allocated to CPAP group and the control group
Time frame: 4 months
Ran from Jul 2020 to primary completion in Oct 2026, 74 months.
Of 511 non-industry interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's 74 months is above that.
Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: primary completion Apr 2025 → Oct 2026 and completion May 2025 → Oct 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Alberto Alonso Fernandez